Brittany Gouse, MD, MPH
Assistant Professor, Psychiatry
Biography
Dr. Brittany Gouse’s MD MPH is the Assistant Clinical Director of the Wellness and Recovery After Psychosis program and Assistant Professor of Psychiatry at Chobanian and Avedisian School of Medicine. She earned MD-MPH through the State University of New York Upstate Medical University and Syracuse University dual degree program. She completed both her Residency in Adult Psychiatry and Fellowship in Public Psychiatry at BU-BMC. Through her Fellowship in Public Psychiatry, Dr.Gouse specialized in the care of individuals living with schizophrenia and other forms of serious mental illness. She sees patients for psychopharmacology in the WRAP program.
Dr. Gouse’s research is predominantly in epidemiology, with a focus on studying the drivers of morbidity and premature mortality in schizophrenia. She co-directs WRAP’s Advancing Coordinated Care through Epidemiologic Studies in Schizophrenia (ACCESS) initiative. She is the recipient of the 2023-2025 BU Clinical and Translational Science Institute KL2 Award and the 2023-2025 American Psychiatric Association Research Fellowship.
Other Positions
- Psychiatrist, Psychiatry, Boston Medical Center
Education
- State University of New York Upstate Medical University, MD/MPH
- Tulane University, BS
Publications
- Published on 3/4/2024
Gouse BM, Weinberg JM, Brown HE. Risk Stratification to Reduce Excess Mortality in Early Psychosis. JAMA Netw Open. 2024 Mar 04; 7(3):e240623. PMID: 38497967.
Read at: PubMed - Published on 4/20/2023
Gouse BM, Schwarz AG, Gibbs JS, Weinberg JM, Yue H, Chava A, Brown HE. Demographic predictors of lack of current mental health treatment among university students with a schizophrenia spectrum disorder. Early Interv Psychiatry. 2023 Dec; 17(12):1207-1215. PMID: 37081818.
Read at: PubMed - Published on 3/20/2023
Gouse BM, Boliver EE, Oblath R, Camacho L, Brown HE. Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits. Psychiatry Res. 2023 May; 323:115151. PMID: 36934468.
Read at: PubMed - Published on 3/17/2023
Gouse BM, Boliver EE, Oblath R, Camacho L, Brown HE. Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits. Psychiatry Res. 2023 Mar 17; 323:115151. PMID: 36934468.
Read at: PubMed - Published on 1/9/2023
Gouse BM, Kline ER. Clinical insights: Preventing psychosis treatment disengagement. Schizophr Res. 2023 Feb; 252:64-66. PMID: 36628870.
Read at: PubMed - Published on 7/1/2022
Gouse BM, Brown HE. Improving Outcomes in Schizophrenia-A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness. JAMA Netw Open. 2022 Jul 01; 5(7):e2224172. PMID: 35900769.
Read at: PubMed - Published on 6/6/2022
Schor SH, Gibbs JS, Gouse BM, Brown HE. A call to action: Increased mortality from COVID-19 among individuals with schizophrenia calls for coordinated vaccination efforts. Schizophr Res. 2022 Aug; 246:63-64. PMID: 35716577.
Read at: PubMed - Published on 2/19/2021
Gouse BM, Nieves-Archibald A, Trutzer I, Rezvani M, Srinath M, Chang A, Wilensky D, Duncan A. Pediatric Malignant Catatonia Associated With Vaporized Cannabis Use: A Case Series. J Acad Consult Liaison Psychiatry. 2021 Jul-Aug; 62(4):445-448. PMID: 34210403.
Read at: PubMed - Published on 8/10/2020
Gouse BM, Spears WE, Nieves Archibald A, Montalvo C. Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism. Brain Behav Immun. 2020 10; 89:529-530. PMID: 32791211.
Read at: PubMed - Published on 6/1/2020
Gouse BM, Chang AL, Smith EG. Effect Size and Blinding in Lumateperone Trial. JAMA Psychiatry. 2020 06 01; 77(6):650-651. PMID: 32320009.
Read at: PubMed
View 7 more publications: View full profile at BUMC